RIÑÓN Y ENFERMEDAD CARDIOVASCULAR - Seden

BIBLIOGRAFÍA
1132. Alexander RW. Hypertension and the pathogenesis of atherosclerosis:
Oxidative stress and the mediation of arterial
inflammatory response. A new perspective. Hypertension
25:155-161, 1995.
1133. London GM, Marchais SJ, Safar ME, Genest AF, Guerin AP,
Metvier F, y cols. Aortic and large artery compliance in endstage
renal failure. Kidney Int 37:137-142, 1990.
1134. Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC,
Peterson D y cols. “U” curve association of blood pressure
and mortality in hemodialysis patients. Kidney Int 54:561-
569, 1998.
1135. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cottini E,
Giacone G, y cols. Prediction of left ventricular geometry by
clinic, pre-dialysis and 24- h ambulatory BP monitoring in
hemodialysis patients: CREED investigators. J Hypertens 17:
1751-1758, 1999.
1136. Wu M-S, Yu C-C, Yang C-W, Wu C-H, Huang J-Y, Hong J-J y
cols. Poor pre-dialysis glycaemic control is a predictor of
mortality in type II diabetic patients on maintenance haemodialysis.
Nephrol Dial Transplant 12:2105-2110, 1997.
1137. Schmidt AM, Yan SD, Wautier J-L,Stern D. Activation of
receptor por advanced glycation end products: A mechanism
of chronic vascular dysfunction in diabetic vasculopathy
and atherosclerosis. Circ Res 84:489-497, 1999.
1138. King P, Peocock I, Donnelly R. The UK prospective diabetes
study (UKPDS): clinical and therapeutic implications for type
2 diabetes. Br J Clin Pharmacol 48: 643-8, 1999.
1139. Attman P-O, Alaupovic P. Lipid an apolipoprotien profiles of
uremic dyslipoproteinemia-Relation to renal function and
dialysis. Nephron 57:401-410, 1991.
1140. Brown G, Albers JJ, Fisher LD, Schaeffer SM, Lin J-T, Kaplan
C y cols. Regression of coronary artery disease as a result of
intensive lipid-lowering therapy in men with high levels of
apolipoprotein B.N Engl J Med 323:1289-1298, 1990.
1141. Metivier F, Marchais SJ, Guerin AP, Pannier B, London GM.
Pathophysiology of anaemia: Focus on the heart and blood
vessels. Nephrol Dial Transplant 15:14-18, 2000.
1142. Fellner SK, Lang RM, Neumann A, Korcarz C, Borow KM:
Cardiovascular consequences of correction of the anemia of
renal failure with erythropoietin, Kidney Int 44:1309-1315,
1993.
1143. Besarab A, Bolton WK, Nissenson AR, Schwab SJ, Goodkin
DA. The Normal Haematocrit Trial in dialysis patients with
cardiac disease. Nephrol Dial Transplant 14:2043-2044,
1999.
1144. Rostand SG, Drüeke TB. Parathyroid hormone, vitamin D,
and cardiovascular disease in chronic renal failure. Kidney
Int 56: 383-392, 1999.
1145. Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T,
Detrano R y cols. Active serum vitamin D levels are inversely
correlated with coronary calcification. Circulation 96:1755-
1760, 1997.
1146. Block GA, Hulbert-Shearon TE, Levin NW, Port FK.
Association of serum phosphorus and calcium x phosphorus
product with mortality risk in chronic hemodialysis patients:
A national study. Am J Kidney Dis 31:607-617, 1998.
1147. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S.
Homocysteine and cardiovascular disease. A critical review
of the epidemiologic evidence. Ann Intern Med 131:363-
375, 1999.
1148. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M,
Vollset SE. Plasma homocysteine levels and mortality in
patients with coronary artery disease. N Engl J Med 337:230-
236, 1997.
1149. Ross R. Atheroesclerosis-An inflammatory disease. N Engl J
Med 40:115-126, 1999.
1150. Libby P, Ridker PM. Novel inflammatory markers of coronary
risk: Theory versus practice. Circulation 100:1148-1150,
1999.
1151. Herrington DM. The HERS trial results: Paradigms lost? Ann
Intern Med 131:463-466, 1999.
1152. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD.
Postmenopausal hormone replacement therapy: scientific
review. JAMA 21;288(7):872-81, 2002.
1153. Stehman-Breen CO, Gillen D, Gipson D. Prescription of hormone
replacement.Therapy in postmenopausal women with
renal failure. Kidney Int 56: 2243-2247, 1999.
1154. Kenny A, Sutters M, Evans DB, Shapiro LM. Effects of hemodialysis
on coronary blood flow. Am J Cardiol 74:291-294,
1994.
1155. Van der Sande FM, Cheriex EC, van Kuijk W, Leuissen K.
Effect of dialysate calcium concentration on intradialytic
blood pressure course in cardiac-compromised patients. Am
J Kidney Dis 32:1125-1131, 1998.
1156. Alpert MA, Wizeman V, Holph KD, Van Stone J, Culpepper
MC. Hemodialysis and the heart.Am J Med Sci 309:110-121,
1995.
1157. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ,
Murray DC y cols. Clinical and echrocardiographic disease
in patients starting end-stage renal disease therapy. Kidney
Int 47:186-92, 1995.
1158. Mehta BR, Ireland MA,Shiu MF. Echocardiographic evaluation
of cardiac size and function in dialysis patients. Clin
Nephrol 20:61-66, 1993.
1159. Ikram H, Lynn KL, Bacley RR,Little PJ. Cardiovascular changes
in chronic hemodialysis patients. Kidney Int 24:371-6,
1983.
1160. London GM, Fabiani F, Marchais SJ, de Vernejoul MC,
Guerin AP, Safar ME y cols. Uremic cardiomiopathy. An
inadequate left ventricular hypethrophy. Kidney Int 31:973-
980, 1987.
1161. Straumann E, Bertel O, Meyer B. Symmetric and asymmetric
left ventricular hypertropny in patients with end-stage renal
failure on long-term hemodialysis. Clin Cardiol 21:672-678,
1998.
1162. London GM, Guerin AP, Marchais SJ. Pressure-overload cardiomyopathy
in end-stage renal disease. Curr Opin Nephrol
Hypertens 8:179-186, 1999.
1163. London GM, Guerin AP, Marchais SJ. Pathophysiology of left
ventircular hypertrophy in dialysis patients. Blood Purif
12:277-283, 1994.
1164. Meeus F, Kourilsky O, Guerin AP, Gaudry C, Marchais SJ,
London GM. Pathophysiology of cardiac disease in hemodialysis
patients. Kidney Int 76 (suppl 1): 140-147, 2000.
1165. Canziani ME, Cendoroglo Neto M,Saragoca MA, Cassiolato
JL, Ramos OL, Ajzen H y cols. Hemodialysis versus continous
ambulatory peritoneal dialysis: effects on the heart.
Artif Organs 19:241-244, 1995.
1166. Amann K, Breitbach M, Ritz E, Mall G. Myocyte/capillary
mismatch in the heart of uremic patients. J Am Soc Nephrol
9:1018-1022, 1998.
222